Olaf van Tellingen Selected Research

Mechanistic Target of Rapamycin Complex 1

1/2020

Comments on: "Synergistic activity of mTORC1/2 kinase and MEK inhibitors suppresses pediatric low-grade glioma tumorigenicity and vascularity".

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Olaf van Tellingen Research Topics

Disease

54	Neoplasms (Cancer) 03/2024 - 08/2004
33	Breast Neoplasms (Breast Cancer) 11/2023 - 04/2002
13	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 04/2005
12	Brain Neoplasms (Brain Tumor) 11/2023 - 07/2003
12	Glioma (Gliomas) 01/2020 - 04/2005
3	Melanoma (Melanoma, Malignant) 03/2024 - 01/2022
3	Neoplasm Metastasis (Metastasis) 10/2023 - 10/2019
3	Diffuse Intrinsic Pontine Glioma 01/2020 - 01/2018
2	Lung Neoplasms (Lung Cancer) 03/2024 - 01/2022
2	Colonic Neoplasms (Colon Cancer) 01/2023 - 05/2013
1	Colorectal Neoplasms (Colorectal Cancer) 01/2023
1	Pancreatic Neoplasms (Pancreatic Cancer) 11/2022
1	Prostatic Neoplasms (Prostate Cancer) 10/2021
1	Rhabdoid Tumor (Rhabdoid Tumors) 11/2020
1	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/2020
1	Infertility (Sterility) 01/2020
1	Poisoning 01/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2020
1	Cardiotoxicity 01/2020
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/2019

Drug/Important Bio-Agent (IBA)

28	Proteins (Proteins, Gene)FDA Link 03/2024 - 04/2002
19	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 11/2023 - 03/2003
7	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2023 - 07/2007
7	ATP-Binding Cassette Transporters (ABC Transporters)IBA 01/2021 - 09/2005
6	Adenosine Triphosphate (ATP)IBA 01/2020 - 07/2007
5	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 05/2014
5	ElacridarIBA 01/2018 - 07/2003
4	Topotecan (Hycamtin)FDA LinkGeneric 10/2023 - 11/2007
4	Phosphotransferases (Kinase)IBA 06/2023 - 01/2018
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023 - 01/2018
4	dipinacoline glutamateIBA 01/2020 - 10/2015
4	AnthracyclinesIBA 01/2020 - 01/2013
3	Docetaxel (Taxotere)FDA Link 01/2021 - 07/2007
3	Histones (Histone)IBA 01/2020 - 01/2013
3	Etoposide (VP 16)FDA LinkGeneric 01/2020 - 03/2003
3	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 01/2012
3	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2018 - 08/2008
3	ATP-Binding Cassette Sub-Family B Member 4IBA 10/2013 - 12/2007
3	Methotrexate (Mexate)FDA LinkGeneric 08/2011 - 08/2004
2	Cytotoxins (Cytolysins)IBA 10/2023 - 01/2008
2	Cytostatic AgentsIBA 01/2023 - 01/2008
2	veliparibIBA 01/2022 - 05/2014
2	palbociclibIBA 01/2022 - 10/2015
2	ChromatinIBA 01/2020 - 01/2013
2	PoisonsIBA 01/2020 - 02/2010
2	Glutamine (L-Glutamine)FDA Link 10/2019 - 02/2016
2	Cisplatin (Platino)FDA LinkGeneric 01/2019 - 07/2007
2	GSK-2816126IBA 01/2019 - 10/2015
2	RNA (Ribonucleic Acid)IBA 01/2019 - 01/2018
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 11/2018 - 05/2014
2	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 11/2018 - 02/2010
2	Taxoids (Taxanes)IBA 01/2018 - 09/2005
2	dactolisibIBA 03/2017 - 07/2012
2	Cyclin-Dependent Kinase Inhibitor p16IBA 05/2014 - 07/2010
2	LuciferasesIBA 01/2014 - 07/2007
2	Multidrug Resistance-Associated ProteinsIBA 04/2013 - 08/2011
2	Irinotecan (Camptosar)FDA LinkGeneric 04/2013 - 01/2012
2	ST 1481 (Gimatecan)IBA 04/2013 - 12/2007
2	tryptoquivalineIBA 01/2013 - 04/2002
2	Topoisomerase I InhibitorsIBA 01/2012 - 02/2010
2	7-hydroxymethotrexateIBA 08/2011 - 08/2004
2	Imatinib Mesylate (Gleevec)FDA Link 02/2009 - 04/2005
2	TrabectedinIBA 01/2009 - 02/2007
2	Tyrosine Kinase InhibitorsIBA 08/2008 - 04/2005
1	VemurafenibIBA 11/2023
1	Adenosine (Adenocard)FDA LinkGeneric 10/2023
1	tyrosine receptor (receptor, tyrosine)IBA 06/2023
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2023
1	CurcuminIBA 01/2023
1	Drug CombinationsIBA 11/2022
1	LY3214996IBA 11/2022
1	N- (3- chloro- 7- indolyl)- 1,4- benzenedisulphonamide (E7070)IBA 01/2022
1	Heparitin Sulfate (Heparan Sulfate)IBA 01/2022
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022
1	Testosterone (Sustanon)FDA Link 10/2021
1	enzalutamideIBA 10/2021
1	Biomarkers (Surrogate Marker)IBA 10/2021
1	selitrectinibIBA 01/2021
1	TropomyosinIBA 01/2021
1	Fluorescent Dyes (Fluorescent Probes)IBA 01/2021
1	Mechanistic Target of Rapamycin Complex 1IBA 01/2020
1	trioctyl phosphine oxide (TOPO)IBA 01/2020
1	Type II DNA Topoisomerases (Topoisomerase II)IBA 01/2020
1	AclarubicinIBA 01/2020
1	Asparaginase (Elspar)FDA Link 10/2019
1	Glutamic Acid (Glutamate)FDA Link 10/2019
1	Aspartic Acid (Aspartate)FDA Link 10/2019
1	AsparagineIBA 10/2019
1	Amino Acid Transport System X-AG (Glutamate Transporter)IBA 10/2019
1	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2019
1	PlatinumIBA 01/2019
1	1- (6- (3,5- dichloro- 4- hydroxyphenyl)- 4- ((4- ((dimethylamino)methyl)cyclohexyl)amino)- 1,5- naphthyridin- 3- yl)ethanoneIBA 11/2018
1	AZD2461IBA 11/2018
1	Antineoplastic Agents (Antineoplastics)IBA 11/2018

Therapy/Procedure

24	Therapeutics 03/2024 - 07/2007
11	Drug Therapy (Chemotherapy) 10/2023 - 04/2002
1	Treatment Delay 03/2024
1	Aftercare (After-Treatment) 10/2023
1	Immunotherapy 11/2022
1	Castration 10/2021